Key Component in Hemoglobin Maturation Process Identified
New findings allow researchers to better identify potential problems in blood development, with potential for use in developing treatments for cancer and blood diseases.
New research from Cleveland Clinic has identified a major player in the process by which hemoglobin (Hb) forms and matures; understanding of this process has been elusive until recently.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The new finding allows researchers to better identify potential problems in blood development, according to one of the researchers, Dennis J. Stuehr, PhD, of the Lerner Research Institute’s Department of Pathobiology. It has potential for use in developing treatments for cancer — since some cancer cells utilize Hb differently than red blood cells — and blood diseases such as sickle cell anemia, thalassemia and anemia, he says. The research was published in the Proceedings of the National Academy of Sciences of the USA.
Specifically, Drs. Stuehr, Arnab Ghosh, PhD, and his colleagues found that a protein called heat shock protein 90 (hsp90) is critical in the development of mature, functional hemoglobin, acting as a chaperone for beta and gamma globins. These globins combine with heme to form mature Hb that can deliver oxygen throughout the body. “Hsp90 is a big guy on the block, and there is even a bi-annual conference devoted to its role and related chaperone machinery,” explains Dr. Stuehr.
Previous research in the field had shown that another chaperone protein called alpha hemoglobin stabilizing protein (AHSP) binds to alpha globins during erythropoiesis.
The researchers studied Hb maturation in three cells lines, both erythroid and nonerythroid: the human erythroid leukemia cell line K562 and human erythroid progenitor cells HiDEP-1 and HUDEP-2 during differentiation, and nonerythroid cell lines that express Hb naturally or in a transient manner. They looked specifically for a role for hsp90 as a chaperone.
In the immature, heme-free state, hsp90 was found to be essential for heme insertion, globin specific, and a driver of globin maturation during erythropoiesis. “We found that hsp90 binds to immature, heme-free beta and gamma globins in erythroid-like cells, stabilizing the globins and helping to drive their heme-insertion reactions,” reports Dr. Stuehr. “Hsp90 then dissociates from the globins and is replaced by a protein partner, allowing heterotetramer formation to occur with globin alpha.” They found that hsp90 did not associate with mature Hb, however, he says.
Hsp90 was also found to drive globin maturation. In nonerythroid cells. “Our work showed that in situations where there is no AHSP protein, hsp90 can take over for that protein and help mature both alpha and beta globins in nonerythroid cells,” he says, adding, “We answered a paradox as to how without AHSP you can get functional, mature hemoglobin outside of the erythroid system.”
Although research is still preliminary, Dr. Stuehr said the potential applications of the Cleveland Clinic hsp90 work are exciting and promising. “For instance, no one has looked at whether this pathway with hsp90 has been compromised under some conditions or in some patients, such as those with blood disorders or cancers,” he says, “and that can now be investigated.”
More immediate implications of the research are for drug development. “Drugs that can block hsp90 in cancer cells are currently being investigated,” he reports, “but it’s been found they can cause negative side effects such as anemia. Our research might allow investigators to target hsp90 inhibitors to the cancer itself so it doesn’t attack other healthy cells in the patient’s body. Ultimately, that could lead to less anemia with use of these drugs. And research already suggests that blocking hemoglobin maturation in certain cancers will inhibit their ability to metastasize. ”
Next on the research agenda, Dr. Stuehr and colleagues intend to search for co-chaperones with hsp90 in the hemoglobin maturation process. “We know hsp90 is not the only protein at work here,” he says, “and we expect to see some familiar faces and some new faces.” They also want to examine how hsp90 interacts with hemoglobin at the molecular and genetic levels, and how it functions normally and in disease conditions that compromise its function.